On November 4, CVS Health said it will split into two public companies by the first half of 2028. The CVS split into two companies separates about 9,000 retail pharmacies into a new company called CVS Pharmacy, while Aetna, the Caremark pharmacy benefit manager, Oak Street Health and Signify Health stay together in a company keeping the CVS Health name. It is one of the biggest corporate breakups in years, and it unwinds a strategy CVS spent nearly two decades building.

That is the story. Not the split itself, but what it admits. CVS spent $69 billion buying Aetna and told the world that owning the whole healthcare chain was the future. Eight years later it is taking the chain apart, and its own chief executive is calling that a position of strength. The market did not agree. Shares fell 12.5 percent on the day, wiping out nearly $15 billion of market value, even though the company beat its earnings expectations.

The CVS split into two companies reverses the $69 billion bet

The Aetna deal was the signature bet of an era. CVS announced in 2017 that it would buy the health insurer for about $69 billion in equity value, $77 billion including assumed debt, and closed the deal in 2018. The pitch was integrated healthcare: one company that sold the prescription, managed the benefit, paid the claim and ran the clinic. CVS had already bought the Caremark pharmacy benefit manager nearly twenty years earlier, and it later spent about $10 billion on Oak Street Health, a primary care chain for older adults, plus Signify Health for in home evaluations. By 2026 the combined company had about 9,000 pharmacies, more than 1,000 clinics, a benefits manager covering about 87 million plan members and insurance products serving about 37 million people.

That was the empire. The problem was never the size of it. The problem was that every piece added a new regulator, a new margin fight and a new management distraction, and the whole ended up worth less than the parts. CVS is now worth about $117 billion on the stock market, and its shares are flat so far this year while the healthcare sector fund is up more than 20 percent. The integration that was supposed to be the advantage became the thing investors wanted taken apart.

The market did not buy it

The timing made the verdict harsher. CVS reported third quarter results the same morning, and they were strong. Revenue was $108.4 billion, up about 5 percent and ahead of the $104.8 billion analysts expected. Adjusted earnings were $2.09 a share against a $1.65 estimate, and the medical benefit ratio, the share of premiums paid out in medical costs, came in at 91.3 percent against a 92.3 percent consensus. Same store sales fell 0.6 percent, but that was better than the 1.4 percent drop analysts feared.

None of it mattered. Shares closed down 12.5 percent at $79.96. Kevin Caliendo, an analyst at UBS, put it plainly: CVS shares are weak despite very strong third quarter operating results because the announced split came as a surprise and is perceived as a defensive move against regulation rather than an offensive move. Barclays analyst Andrew Mok pointed to a lack of financial detail around the breakup, and noted that when CVS bought Caremark twenty years ago it promised synergies of at least $500 million. Kevin Gade of Bahl and Gaynor said investors were asking why they should lean into a story facing an earnings hiccup in 2027, a year when rivals are seeing accelerating growth, even though CVS forecast 2027 adjusted earnings of at least $8.65 a share, ahead of the $8.53 analysts expected.

Not every analyst called it a retreat. Michael Cherny of Leerink Partners said the split feels like a complete shock, but added that the retail pharmacy business has been performing well, winning market share from competitors and seeing stabilizing gross margins thanks to CostVantage, the new pharmacy reimbursement model CVS introduced last year. In that light, he wrote, the outlook for a standalone retail pharmacy with meaningful scale and leverage on its own may be stronger now than before.

Chief executive David Joyner defended the move on the analyst call. “We are not doing anything out of a distressed decision,” he said. “We are doing it because we have healthy balance sheets with appropriate capital allocation opportunities and momentum in each one of the businesses that we are operating.” He has reason to sound confident. Shares have risen about 70 percent since he took the helm in October 2024. But a chief executive does not break his company in two because the model is working. He does it because the model stopped working and the market finally said so out loud.

The pressure CVS will not name

Joyner did not blame regulation, but the analysts did, and they may be right. Ann Hynes, an analyst at Mizuho Securities, wrote that the decision is largely driven by mounting legislative and legal pressures surrounding vertically integrated healthcare companies, particularly pharmacy benefit managers. That is analyst interpretation, not CVS’s stated reason, and it should be read as such. But the pressure is real and it is documented.

In February, Senators Elizabeth Warren and Josh Hawley introduced the Break Up Big Medicine Act, a bipartisan bill that would bar common ownership of medical providers with insurers, pharmacy benefit managers or drug wholesalers, giving companies one year to divest. The bill drew support from Mark Cuban. Three pharmacy benefit managers, CVS Caremark, Express Scripts and Optum Rx, handle about 80 percent of prescription drug claims in the United States. The Federal Trade Commission is already investigating the industry. Arkansas has passed its own law barring pharmacy benefit managers from owning pharmacies.

None of this proves CVS split because of Washington. But a founder reading the announcement should understand the direction of travel. When the largest players in an industry are also its most scrutinized, owning every link in the chain stops being a moat and starts being a target. CVS is getting out ahead of a fight it may not be able to win, and doing it on its own timetable rather than a regulator’s.

What founders should steal

Own the step you can be best at, and partner for the rest. That is the lesson, and it has three lines.

First, buying the chain only works if you can run every link better than the specialists already running it. CVS bought a pharmacy benefit manager, an insurer, a primary care chain and a home health business, and each one needed a different kind of management, a different regulator and a different margin structure. The company that ran 9,000 drugstores well was not automatically the company that could run an insurer well. Second, integration is a cost, not just a synergy. Every acquisition added meetings, reporting lines and compliance work that pulled attention away from the stores where customers actually walk in. Third, watch what the market rewards. Investors sent the shares down 12.5 percent on a day the company beat earnings, because they were pricing the breakup, not the quarter. The market was telling CVS that two focused companies are worth more than one sprawling one.

There is one more thing founders should steal, and it is the least comfortable. The split is not done. It still needs final approval from the CVS board, an effective Form 10 registration statement with the Securities and Exchange Commission, and confirmation that the separation is tax free for the company and its shareholders. CVS itself says there can be no assurance the separation will occur, or that it will occur on the terms or timeline described. Goldman Sachs is leading the advice, with Consello and the law firm Wachtell Lipton alongside. Both resulting companies are expected to carry solid investment grade ratings, generate strong free cash flow and pay an attractive dividend. Shareholders will own shares in both.

The direction is set even if the paperwork is not finished. The era of healthcare gigantism is ending, and the company that built the biggest version of it just said so out loud. Founders who still dream of owning the whole value chain should read this split as a warning written in their own language: buying everything is easy. Running everything is the hard part, and the market has stopped paying for it.